FDA News Release FDA approval brings first gene therapy to the United States The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA… Read more »
Category: News
New Targeted Funding Call is Now Open
*TARGETED FUNDING CALL: BioCanRx is pleased to announce that the next call for applications is now open in the Clinical, Social & Economic Impact (CSEI) program. At this time, BioCanRx is placing highest priority on the intake of new applications for funding, in the area of development and application of early Health Technology Assessment (HTA)… Read more »
Next Funding Call for Applications is Now Open
*PRIORITY FUNDING CALL: BioCanRx is pleased to announce that the next call for applications is now open in all of the Catalyst, Enabling, Clinical Trial, and Clinical, Social & Economic Impact (CSEI) programs. At this time, BioCanRx is placing highest priority on the intake of new applications for funding, proposing research activities that would be likely… Read more »
BioCanRx and Partners Announce Funding for a New Clinical Trial to Treat Hematologic Cancers
OTTAWA, ON – Wednesday, August 2, 2017 – BioCanRx and its partners today announce $2,832,397 in funding for two collaborative research projects including a clinical trial aiming to treat hematologic cancers with MiHA-targeted immunotherapy. These projects come out of the latest round of BioCanRx’s full applications. Funding partners for these projects include Centre intégré universitaire de… Read more »
2017 Summit for Cancer Immunotherapy
Making Breakthroughs, Building Partnerships and Advancing Next-Generation Treatments This year’s successful Summit for Cancer Immunotherapy (Summit4CI) saw more than 320 leading scientists, clinicians, trainees, not-for profit stakeholders, patients, government officials and industry representatives come together to share knowledge, learn and network. The Summit took place in Gatineau, Quebec, in late June and explored… Read more »
Removing obstacles to innovation: BioCanRx core facilities provide essential manufacturing, immune analysis services
By: Heather Blumenthal Immunotherapy is enormously promising for cancer treatment. But while every day research is every day advancing the area, thanks in part to funding from BioCanRx, it is expensive – and that expense pales in comparison to the cost of bringing a discovery out of the lab and into human trials and… Read more »
Training is the name of the game at Summit4CI
by Jovian Tsang The Summit for Cancer Immunotherapy took place in Gatineau, Quebec from June 25 to 28. It was jam-packed with training opportunities created for, and by, highly qualified personnel (HQP). Below you’ll find some highlights. Enjoy! Continuing BioCanRx’s commitment to training HQP, this year’s pre-Summit HQP training day focused on hiring… Read more »
Piloting a new Learning Institute at Summit4CI
The 2017 BioCanRx Learning Institute Dissemination Report By The Learning Institute Developers and Organizers The BioCanRx-Cancer Stakeholder Alliance Learning Institute debuted at this year’s Summit for Cancer Immunotherapy. The pilot model was developed and organized by members of the Cancer Stakeholder Alliance Working Group and HQP community. The Learning Institute brought together patient/public… Read more »
Ottawa cancer researchers to play lead role in new immunotherapy initiative, worth $4 million
By: The Ottawa Hospital Research Institute The Ontario Institute of Cancer Research (OICR) has awarded $4 million to a team of researchers working to harness the immune system to attack cancer. Called cancer immunotherapy, this area of research was dubbed “breakthrough of the year” by Science in 2013 and has been growing ever since…. Read more »
BioCanRx and partners announce $6.5M in funding for three new projects including a clinical trial
OTTAWA, ON – Thursday, May 4, 2017 – Today, BioCanRx and its partners announce $6,559,857 in funding for three collaborative research projects including a clinical trial that will have five sites throughout Canada. These novel therapies projects come out of the latest round of full applications. Funding partners for these projects include Turnstone Biologics, Ovarian… Read more »
